Calydon Capital Sells 16,804 Shares of Novo Nordisk A/S $NVO

Calydon Capital trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 65.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 8,979 shares of the company’s stock after selling 16,804 shares during the period. Calydon Capital’s holdings in Novo Nordisk A/S were worth $498,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in NVO. Cavalier Investments LLC boosted its holdings in Novo Nordisk A/S by 81.2% during the third quarter. Cavalier Investments LLC now owns 41,537 shares of the company’s stock valued at $2,305,000 after acquiring an additional 18,608 shares during the period. Chevy Chase Trust Holdings LLC grew its stake in shares of Novo Nordisk A/S by 20.4% in the third quarter. Chevy Chase Trust Holdings LLC now owns 4,449 shares of the company’s stock worth $247,000 after acquiring an additional 753 shares during the last quarter. Community Bank N.A. bought a new position in Novo Nordisk A/S during the third quarter worth $45,000. Clear Street Group Inc. acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at $56,378,000. Finally, Azimuth Capital Investment Management LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter valued at $230,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Trading Down 0.1%

NVO stock opened at $37.99 on Monday. Novo Nordisk A/S has a 1-year low of $35.85 and a 1-year high of $82.57. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average is $50.14 and its 200-day moving average is $51.73. The firm has a market cap of $169.61 billion, a P/E ratio of 10.95 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Analysts Set New Price Targets

Several research firms have issued reports on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research note on Tuesday, March 3rd. HSBC restated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Finally, TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.